NXY-059 for Acute Ischemic Stroke

Abstract

The administration of NXY-059 within six hours after the onset of acute ischemic stroke significantly improved the primary outcome (reduced disability at 90 days), but it did not significantly improve other outcome measures, including neurologic functioning as measured by the NIHSS score. Additional research is needed to confirm whether NXY-059 is beneficial in ischemic stroke. (ClinicalTrials.gov number, NCT00119626.).

Keywords

Affiliated Institutions

• Western Infirmary GB
• AstraZeneca (United States) US
• Hospital Universitari Germans Trias i Pujol ES
• The Royal Melbourne Hospital AU
• University of Duisburg-Essen DE
• The University of Melbourne AU
• AstraZeneca (Sweden) SE
• The University of Texas Health Science Center at Houston US
• Universitat Autònoma de Barcelona ES
• University of California, San Diego US
• University of Alberta CA

Related Publications